Ranjit Banwait, MD, M.Sc

@providencecol educated II @RCSI_Irl & @ucf_im_gnv_ trained II @UTHealthSA & @UTHealthSAMDA Geriatrics & HemeOnc fellow II part-time marathoner

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

@mazo_md @mayscancer Congrats! 🍾

[NEJM @NEJM]

Presented at #ASCO25:

A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: https://t.co/j3kWJDjuVz

@ASCO

[UT Health SA Hematology/Oncology Fellowship @LSOM_HemOnc]

Celebrating the Class of 2025 Hematology/Oncology fellows last night! Congratulations! We are so proud of all your hard work and accomplishments @mayscancer @UTHSAResearch @HemOncFellows @ranjitbanwait @AggieMD @DrSAHaddad @mazo_md

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

Excited to share our work published today. Shout out to @VKaklamani for her amazing mentorship! @UTHealthSAMDA
Pilot phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors - https://t.co/Tnt13yA2bd

[VIRGINIA KAKLAMANI @VKaklamani]

Our cancer survivorship walk/run. Fellowship program represented @LSOM_HemOnc @UTHealthSAMDA

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

I just registered for Give Cancer the Boot Survivorship 5K and 1-Mile Walk. Why don't you join me? 🏃‍♂️🏃‍♂️🏃‍♂️ https://t.co/lK2ftQH5iG

[Paolo Tarantino @PTarantinoMD]

The history of #SABCS reviewed by @VKaklamani. The first symposium was held in 1978, with 30 attendees and talks by Drs Fisher and Lippman. #SGBCC2025

[VIRGINIA KAKLAMANI @VKaklamani]

Please consider registering ⁦@_MDEducation⁩

[VIRGINIA KAKLAMANI @VKaklamani]

Great #sabcssnippet on approval of datodxd. @hoperugo @KateIdaLathrop @SABCSSanAntonio @UTHealthSAMDA @AACR https://t.co/eYI82pmApl

[Paolo Tarantino @PTarantinoMD]

Simultaneous @NatureMedicine pub of 2 neoadjuvant chemo-IO trials for high-risk ER+ BC: KN-756 & CM-7FL. Both found a striking improvement in pCR rate with IO, with larger Δ if PD-L1+ or low ER. Waiting for EFS data, which will most likely impact practice. https://t.co/JhZ3vbePyG

[Dr Akhil Santhosh MD DM MRCP(UK) @tuttsakhil]

Money slide💰: Snapshot of survival data for all 1st line CDK4i trials in advanced breast cancer

[FDA Oncology @FDAOncology]

FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
https://t.co/EeMNpgVuYN
#OCENewsBurst

[VIRGINIA KAKLAMANI @VKaklamani]

Setting up for #sabcs24 underway. To all who are traveling to San Antonio safe travels.@SABCSSanAntonio @AACR @UTHealthSAMDA

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

Busy but exciting morning presenting our study on Phase II trial w/ Lenvatinib + Eribulin combo in advanced solid tumors at #ASCO24 Shout out to @VKaklamani @LSOM_HemOnc @UTHealthSAMDA for the support!

[International Society of Geriatric Oncology (SIOG) @SIOGorg]

Registration for the #SIOG2024 Annual Conference is NOW open!
Reserve your spot to meet in Montreal, Canada, on 17-19 October.
The deadline for Early Registration is 22 August. #GeriOnc
Register NOW! https://t.co/dbSABLcL51

[UT Health SA Hematology/Oncology Fellowship @LSOM_HemOnc]

EVE trial update: secondary VTE prevention in cancer patients. Lower dose of apixaban 2.5mg vs 5mg did not lower combined bleeding event. Similar recurrent VTE or arterial thrombosis rates in both groups.
Led by our faculty, Dr. Usha Perepu!
https://t.co/voe3VlKMD6

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

Ecstatic to have received @ASCO @ConquerCancerFd Merit Award for our poster abstract at #ASCO24. Grateful for amazing mentorship from @VKaklamani @DrSukeshiArora @mazo_md and Dr. Kate Lathrop @UTHealthSAMDA

[Ilana Schlam @IlanaSchlam]

2023 was an outstanding year for breast cancer research
As we start wrapping up #SABCS23, we need to think about how to incorporate what we learned in the clinic and future research.
Looking forward to what is yet to come to improve outcomes for our patients!
@OncoAlert #BCSM

[Ranjit Banwait, MD, M.Sc @ranjitbanwait]

Love this PREFERABLE-EFFECT study by Netherlands group at #SABCS23 showing decreased fatigue and increased QOL with structured exercise program in advanced breast cancer pts. Does it have a role in endocrine resistance? @VKaklamani @mazo_md

[VIRGINIA KAKLAMANI @VKaklamani]

Just walked over to the convention center. Everything is getting ready for #sabcs23. Weather sunny and in the 60s. Excited about all the science. @SABCSSanAntonio @AACR @CarlosArteagaMD @hoperugo @DrWGradishar @dradityabardia @matteolambe @OncoAlert